Tag: Medical device

orange and blue BD logo on the wall outside a BD site

85 new jobs are created as BD expands its Wexford medtech manufacturing facility.

With locations in Dublin, Drogheda, and Limerick, BD has been an employer in Ireland for many years. It has invested €4 million in a new R&D facility in Dublin.

The medtech multinational BD has revealed that it would be making two major multimillion-euro investments in its businesses in Ireland.

The corporation is investing €30 million in enlarging its Enniscorthy, Co. Wexford, manufacturing site. In order to simplify the production of medical technology by BD’s Peripheral Intervention business unit, it plans to construct an extra 40,000 square feet of space.

According to the business, the investment would bring more than 85 new jobs to Wexford.

Along with the Wexford investment, BD also marked the opening of its new €4 million research and development facility in Blackrock, County Dublin.

The commercialisation of BD’s first on-body injector technology will be the main focus of the Dublin centre. The staff will collaborate closely with the 300-person Limerick R&D site, which houses BD’s other R&D facility.

At the inauguration ceremony for the Dublin building, BD shared the news about the Wexford expansion and job openings.

Since 1964, BD has operated in Ireland. Since then, it has opened four facilities across the nation, employing more than 1,100 personnel. The government is funding this new investment through IDA Ireland.

In 2021, BD increased both the size of its Drogheda presence and the size of its Limerick R&D facility, adding a total of over 200 positions to both.

Find out more about BD in Ireland.

BD, Dublin, manufacturing, Medical device, Medtech, WEXFORD


Vivasure Medical of Galway raises €30 million for its vessel closing technology.

Vivasure has also received FDA clearance to begin a pivotal study for its synthetic PerQseal implant, which seals blood vessels from the inside has invested €30 million in Galway’s Vivasure Medical to support the development of its vessel closing technology.

The business has created a tool called PerQseal that seals blood vessels from the inside and restores the artery or vein to its original form without leaving any material residues behind.

According to Vivasure, this is the first synthetic implant that is completely absorbable and sutureless for large-bore arterial vessel punctures. The medtech company added that PerQseal’s market is thought to be worth more than €300 million yearly.

The €30 million investment was made as a part of the Series D funding round for Vivasure, which collected €22 million in May to pay for the technology’s clinical development and regulatory approval.

US-based Haemonetics is a worldwide supplier of blood and plasma supplies and services. The company joins current investors Fountain Healthcare Partners, Orchestra BioMed, LSP Health Economics Fund, Panakès Partners and Evonik Venture Capital, which all previously invested in the round.

The US Food and Drug Administration (FDA) has also given Vivasure permission to conduct a pivotal trial for its PerQSeal system.

The FDA has given the medtech an investigational device exemption, enabling Vivasure to move forward with its patch study to assess the device’s safety and efficacy.

There will be 188 patients in this clinical trial from the US and Europe. In order to introduce the PerQseal system commercially, Vivasure intends to use the findings of this research to support a pre-market approval application to the FDA.

Medical device

Cerenovus to make a €50 million investment in Galway site.

Johnson & Johnson neurovascular group Cerenovus invests €50m in their Galway site situated in Ballybrit Business Park.

The investment will be made over the following three years, and 30 new jobs will be created as a result. The funds will be used to expand the company’s research and development efforts, which are part of Johnson & Johnson Medical Devices.

The new financing will allow the Galway plant to continue to be a world-leading centre for stroke treatment development.

Cerenovus has recently extended its Galway location, which now includes a stroke simulation laboratory as well as improved prototype development and testing capabilities.

Meeting and collaboration facilities, as well as a space to allow team and physician partnerships with an emphasis on research, innovation, and product development, have been added to the office space.

According to Micheál Coughlan, Managing Partner InterSearch Ireland and Head of the InterSearch Worldwide Global Medical Devices Practice Group “further investment by J&J in Cerenovus is a positive reflection on the current team and the ability to attract future talent in the Galway region to advance R&D initiatives in the treatment of stoke”

Cerenovus, Galway, Medical device

CroíValve, an Irish medtech company, has raised €8 million for a clinical trial.

CroíValve is an Irish medical device company in early stages, established in 2019. The company is working on developing a minimally invasive device to treat Tricuspid Regurgitation (TR) and it has extensive clinical, technological, and commercial experience. CroíValve are based at Trinity College Dublin. Chief executive Lucy O’Keeffe and R&D director Gavin Kenny lead the company.

CroíValve is working on a minimally invasive treatment for severe TR. It’s an obvious unmet clinical need that has a big influence on mortality, quality of life, and cardiovascular events. TR is the next structural heart opportunity, with a prevalence larger than aortic stenosis in the population over 65 years. The CroíValve DUO Tricuspid Coaptation Valve System is a unique strategy that combines repair and replacement to give the appropriate heart the best option.

The €8 million investment in funding will go toward completing feasibility studies in Europe and the United States, which are required before the device can be approved and put on the market. CroíValve previously raised €10 million.

TR is a serious heart ailment in which the tricuspid valve does not seal properly. This causes debilitating symptoms by pumping blood backwards into the right atrium and venous system. The DUO System comprises of a coaptation valve implant that restores valve function by working in tandem with the native tricuspid valve.

Every year, more than 550,000 people in the United States and the European Union are affected by TR. However, due to their frailty, only a small percentage of these mainly elderly patients obtain surgical therapy.

According to Micheál Coughlan, Head of the InterSearch Global Medical Devices Practice Group & Managing Partner InterSearch Ireland “this further investment is a great vote of confidence in CroíValve and will allow further valuable work to be undertaken in order to bring the product to market”.

CroíValve, InterSearch, Medical device, Medtech Ireland


Finesse Medical to create 200 jobs in Longford as part of expansion

Company was acquired by New York-listed Avery Dennison in a big deal last year

Written by Charlie Taylor

Reposted by InterSearch Ireland


Longford-based manufacturing company Finesse Medical, which was acquired by New York-listed Avery Dennison in a multimillion euro deal last May, is to create 200 jobs locally over the next four years.

The news was announced as its parent revealed plans to expand it medical product manufacturing operations at the Longford facility.

For more on this please click on the link below


Image (http://www.finessemedical.com)

Finesse, jobs, Longford, manufacturing, Medical device

We use cookies to give you the best online experience. By agreeing you consent the use of cookies in accordance with our Privacy Statement and cookie settings in your Privacy Settings below.

Privacy Settings saved!
Privacy Settings

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie

Decline all Services
Accept all Services